Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis.
about
Identification of IFRD1 as a modifier gene for cystic fibrosis lung diseaseNebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosisEndotoxin inhalation alters lung development in neonatal miceIL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice.Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophilsBergamot (Citrus bergamia Risso) fruit extracts and identified components alter expression of interleukin 8 gene in cystic fibrosis bronchial epithelial cell lines.Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis.Clinical significance of microbial infection and adaptation in cystic fibrosis.Neutrophilic airway inflammation and IL-17.Pediatrics, surfactant, and cystic fibrosis in AJRCCM 2002.Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease.Interleukin-10 inhibits elevated chemokine interleukin-8 and regulated on activation normal T cell expressed and secreted production in cystic fibrosis bronchial epithelial cells by targeting the I(k)B kinase alpha/beta complexInflammatory markers of lung disease in adult patients with cystic fibrosis.Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.Pathogen-host interactions in Pseudomonas aeruginosa pneumoniaUpregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosisProphylactic antibiotics in cystic fibrosis: a conviction without evidence?Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia.X-Box-Binding Protein 1 and Innate Immune Responses of Human Cystic Fibrosis Alveolar Macrophages.Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases.Cystic fibrosis: a mucosal immunodeficiency syndrome.Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airwaysGene therapy for the treatment of cystic fibrosis.Extracellular purines are biomarkers of neutrophilic airway inflammation.Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation.Defective CFTR- β-catenin interaction promotes NF-κB nuclear translocation and intestinal inflammation in cystic fibrosis.Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responsesCell therapy for cystic fibrosis.CFTR and Ca Signaling in Cystic Fibrosis.NHERF1 and CFTR restore tight junction organisation and function in cystic fibrosis airway epithelial cells: role of ezrin and the RhoA/ROCK pathway.Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cellsCFTR negatively regulates cyclooxygenase-2-PGE(2) positive feedback loop in inflammation.Impaired interleukin-8 chemokine secretion by staphylococcus aureus-activated epithelium and T-cell chemotaxis in cystic fibrosis.Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice.Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells.Pseudomonas aeruginosa pyocyanin modulates mucin glycosylation with sialyl-Lewis(x) to increase binding to airway epithelial cells.Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis.Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis.Wet cough in children: infective and inflammatory characteristics in broncho-alveolar lavage fluid.Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors.
P2860
Q24621702-4824E155-756B-4785-9318-54F979892572Q28305590-D182EFC6-D605-4452-81A6-883291BD385FQ28393349-8AFF449E-5BB7-46E1-968B-B6A46734A2C6Q33740448-0C8DA876-9E2C-442C-8912-49255B7A4960Q33788110-2D763524-7A6D-444C-A25E-C22F40AD83ADQ33874258-C6E9DE01-15F0-4BAB-965C-4F3D7DC569E2Q33900765-31D98351-D2E5-4BC5-88D0-8D04B6495F57Q34491552-BD628FC3-DBCB-4AA8-956B-93983AAA66FAQ34778056-E897A8CC-EE9C-42A2-99F0-30ED6D4D7261Q35055452-B92607F6-F53D-4544-BF01-82CB52F117D3Q35618493-D6926B42-B24A-4005-89C8-657730DE68E1Q35748847-6730017F-E4FC-4655-8F6E-818157138612Q35749974-4FBB9158-FFF3-4B8A-9698-C7F3D143E8D3Q35917498-8C1D6FC9-071B-4502-A021-B6FD9DE14CBFQ36032639-A29033F1-F5E3-49AA-94EE-3F9914390E60Q36184104-126452C6-97DC-4E8A-B5FE-CDB82AE4728BQ36275138-01BB5F8B-3195-4C6B-87EB-2C36C850CDDFQ36356523-6B5BB589-1812-4246-93D2-4CD5007F415EQ36516884-21B602EC-FB03-4BDC-A086-DD4FADBFB8E5Q36594528-572FF9CD-2CFC-49F6-9406-6F82DCB4BBB3Q36623329-347571C7-A144-45B2-8BC9-F22694E1A887Q36675994-CAFEA271-083F-45BD-BF78-111B738FD0D9Q36925241-C4402ACE-191F-4771-B5B5-D95138897DFCQ37297168-8B6A5B3C-5046-46FA-9AD5-B6FBE8896422Q37631563-323EC689-C877-4ED0-915D-581738FEB336Q37665560-212F919B-B945-42D1-BFCB-515DC014DA80Q37804627-145AF85B-3209-463A-BD62-9E8B58CF7545Q38124849-3F15087C-493C-49F0-BFB8-DEC2AE8591BCQ38811524-5B85EB1B-27DB-40B5-B18E-13EA58F890C1Q39281815-E7D34F00-1713-4603-B3BF-A4B1C76B2DDCQ39456654-53B1FDB5-ED1A-4E06-89BF-EA32DFABB365Q39474714-3B0D7D3C-A537-4CDA-BAED-C6F6E9AD10EAQ39825776-C795CB22-9D3D-421F-9BDB-D4D50A7E5553Q40175734-BEB9126C-9D42-496A-A730-F63CD3AFB1B3Q40185293-93FE4E24-2DFB-45F3-B168-FB2B1CFFBC94Q40915149-0EC8C242-734F-4313-AEFC-04C2E8D729DEQ42527351-7F17D163-6285-4CE0-80B2-572FD2B8074DQ43244889-FECF9A70-58FA-49A5-B5CA-E0034BB09604Q43775538-886B730A-9142-495A-BCBE-470DBC3D2890Q43810702-94173746-4009-4E07-A14A-3BD98EDBC179
P2860
Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@en
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@nl
type
label
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@en
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@nl
prefLabel
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@en
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@nl
P2860
P921
P1476
Endotoxin activity and inflamm ...... patients with cystic fibrosis.
@en
P2093
Marianne S Muhlebach
Terry L Noah
P2860
P304
P356
10.1164/AJRCCM.165.7.2107114
P407
P577
2002-04-01T00:00:00Z